You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Highly efficient, compact, picosecond green laser for time resolved fluorescence

    SBC: ADVR, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): The primary goal of the Phase I effort is to establish the feasibility of fabricating waveguides to realize a significant, (10 fold), increase in performance in the output power of a picosecond pulsed green laser without increasing the peak pump power. The ultimate goal is to develop a fiber pigtailed, compact, cost-effective 530 nm picosecond laser producing 1 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. A NEW BIOSENSOR BASED ON CATASTROPHIC PROTEIN CHANGES

    SBC: ATERIS Technologies            Topic: NIEHS

    DESCRIPTION (provided by applicant): This Phase I project will test the idea that mechanostress-sensitive, fluorescent polymers can detect structural changes induced in proteins following reaction of the protein with small molecule inhibitors. This concept will be tested and proven using recombinant acetylcholinesterase (AChE) an enzyme that is known to undergo catastrophic denaturation when it re ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS

    SBC: SENSOPATH TECHNOLOGIES, INC.            Topic: NCI

    The objectives are to further the pre-clinical development of unique two-photon activated Photodynamic Therapy (PTD) triads that incorporate a photosensitizer, a tumor receptor targeting group, and an imaging functionality, providing a noninvasive treatment of recurrent and refractory Head and Neck (HandN) tumors deep below the skin surface, in an outpatient setting.

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Immunotherapeutic Biomaterials for Treatment of Glioma

    SBC: IN CYTU, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): A Phase I SBIR program of preclinical development is proposed focusing on the development of an active specific immunotherapeutic called Cellarium for treatment of glial cell-based cancers. Successful completion of this project will establish the minimum level of therapeutic feasibility and lead to further development of the vaccine in preparation for f ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Heat Stable Alkaline Phosphatase from Thermophiles

    SBC: J.k. Research            Topic: N/A

    N/A

    SBIR Phase I 1993 Department of DefenseArmy
  6. Develop Enironmental Monitoring Capability for Intergrating Recent Technological Advancements into a Hybrid Artificial Neural Network System

    SBC: SEACORP, LLC            Topic: N/A

    We propose to develop an Environmental Monitoring System by integrating various technologies to create a hybrid artificial neural network system. By functionally decomposing the requirements of environmental monitoring we can apply emerging technologies to fulfill these modularized requirements. Ten (10) years of experience indicate that the technologies directly applicable to specific requirement ...

    SBIR Phase I 1993 Department of DefenseArmy
  7. Lung nodule detection using 3D visual palpation via standard thoracoscopes

    SBC: LUCIDUX            Topic: NIBIB

    DESCRIPTION (provided by applicant): Surgeons perform tens of thousands of operations each year to resect suspicious lung nodules. Historically this necessitated an open surgical approach (thoracotomy) through a large chest wall incision. Over the last 10-15 years, minimally invasive surgical (MIS) approaches have become increasingly common in abdominal and thoracic surgery, with significant benef ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Topical Choroid Plexus Factor Product to Accelerate Wound Healin

    SBC: CYTOSOLV INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic superficial wounds are difficult to treat and often never completely heal. Diabetic foot complications account for the majority of lower limb amputations in the world, and 25% of all diabetic hospital admissionsin the US. The standard of care for these wounds has been unchanged for decades, and remains reduced weight bearing, debridement, antibiotics, a ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Fast and Accurate Tools for Measuring Fluorescence in Living Cells

    SBC: MONTANA MOLECULAR LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Project Summary/Abstract Drug discovery depends crucially upon reliable assays for biological activity. Live cell assays provide a rich environment for measuring biological activity. Coupled with genetically encodedfluorescent biosensors, live cell assays have the potential to provide read-outs with unprecedented specificity for particular signaling pathway ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Treatment of stroke using a novel PDZ binding peptidomimetic drug.

    SBC: Ardane Therapeutics Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Abstract Stroke is the third leading pathological cause of death, behind heart and cancer (NCHS mortality data.). We are developing a new drug, CN 2097, that has demonstrated therapeutic potential for stroke. CN 2097 obstructs the propagation of the cell death signal whilst not interfering with normal neuronal transmission, thus reducing the incidence of si ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government